Amarin Corp PLC (AMRN) Options

Interesting purchase agreement involving vendor Aquabounty appeared on the IHub message board of that company. The shares of that company rose above $1.00/share AH yesterday. Lengthy SEC filing. Salmon raising via aquaculture in land-based facilities likely involved if my memory is correct. A Canadian company is purchaser. Patents and trademarks involved. I skimmed the SEC filing...... Didn't see the facts below.
Extensive litigation concerning safety of genetically engineered salmon eggs and resulting salmon vis a vis wild salmon found Aquabounty the loser. FDA approval of the company product in 2015 was challenged in Court, found unlawful  under environmental protection laws, and potential customers like Red Lobster and Legal Seafood expressed no interest in the product. The company shut down its operations last December. 

Hello KennyBoy, there are many here, including me who are pondering that question. I'm sorry to say that I don't have any answers for you. There are some people who claim that R/S invites short sellers while others say it invites M&A candidates who don't want to look foolish buying a company whose stock is about to be delisted. Good luck to you and all of us. 

You are correct North.  It should be NVS.  They actually should have jumped on Amarin when their mixed omega product failed.

NVO? Or NVS like I opined? Actually I have no clue on either, or any potential buyer with worldwide presence. The Bhatt editorial sent our way today should serve to clear up loose ends in some minds that chose to see ambiguities. I'm not at all sure about any AVXL buyout timing either.

But his shares mysteriously re-appeared

No change
https://www.sec.gov/Archives/edgar/data/897448/000114036123056279/ef20015926_sc13da.htm

https://www.sec.gov/Archives/edgar/data/897448/000089914025000466/xslSCHEDULE_13D_X01/primary_doc.xml

Dear Captain beer:
May ask some advice from you regarding the upcoming reverse spilt on April 12, 2025.
I have bought shareas ranging from $1.50 to $22.0 per share with a total of 200,000 shares. Would you recommend selling all the shares before the split? Would appreciate any other constructive suggestion. Thanks in advance

Given the status of Dr. Bhatt (and all of his
corporate connections) I often wonder what
he thinks should happen with AMRN. Bhatt
is on the BOD of BMY and I would think his
interest would be in seeing his baby (Vascepa)
ultimately be used to benefit as many patients
as possible. Given his professional presentations
seem to culminate in the fact that Vascepa is a
truly effective drug with a myriad of uses...I
can't imagine he would go through all of this
for nothing. I also wonder what he makes of
the new formulations of EPA.

Is anyone else going to vote against current board members retaining their positions at the annual general shareholder meeting?
Sleven,

Sounds like a way NVO can get their hands on V, without automatically burdening themselves with all the mess with litigation and Generics.  If that situation ultimately clears itself up they could then come.  Kind of like a CVR in some sense.  The big questions are:  are they interested and will they move on it. 

North, I am also invested in AVXL. Do you think any potential buyout there will wait to see what the EMA does in terms of approval first?

Hey Lizzy, I've been buying TSLA and I'm dealing with a whole planet full of activists. Bunch of morons!

It was Engine Capital.

North, just heard on CNBC that LYFT will be dealing with an activist didn't catch the name. Good Luck

How does idea of NVS buying AMRN's ex-United States and Canada assets post April 11 2025 with a first, maybe unconditional, option to purchase remaining assets (at a date and price to be determined ) strike you and anybody else? That could provide some time for litigation items to disappear and new Amarin product to be fully developed and NDA filed. 

I can tell I'm getting bored. I bought SHEL shares this morning before I learned of rumor of buyout of BP. I also bought shares of LYFT with thought that AMZN might initiate a buyout. I'm patiently waiting for potential buyout of our BB and AVXL shares; we have less than ten thousand shares of each.

DMC8, thanks for sharing SanDiegoLivings posts....... I look forward to seeing those and they continue to provide positive messaging to what has been a gloomy investment.

https://stocktwits.com/SanDiegoLiving/message/609177443

Got it. I must have been mistaken on shareholder approval.

I agree on the Board. Other than PWO, I actually really liked the makeup of the prior board. Far more pharma experience than the current board, more M&A experience, and I also felt that that board had more commitment specifically to Amarin. I believe the current board is a bunch of placeholders that are not committing as much time and effort to Amarin. There's a few that have some value, but mostly warm bodies that are Sarissa friends/employees.

JRoon, Shareholders don't get a vote on shelf registrations. We do get a vote on board members. I recommend voting against any and all of the current board.
Sleven,

Capt, I thought I'd share this connection with you. The JELIS study dates back many years I happen to be interested in the significance of the timeline e.g., connecting the dots to current studies and who was instrumental in discovering the efficacy of EPA.
Mitsuhiro Yokoyama was instrumental in the JELIS outcome. If you scroll down to the very bottom of the link below *Mochida Pharma supported the JELIS study. That's why our collaboration with Mochida is so significant. I believe eventually some additional patents will show up, which will further assist Amarin with either FDC or LR-EtEPA developments. Both add value to offer BP when the time comes to sell the company.

https://www.sciencedirect.com/science/article/abs/pii/S0002870303003673

More from the article:

$AMRN https://www.sciencedirect.com/science/article/pii/S2452302X24003735
Dr. Deepak Bhatt:

Inflammation contributes centrally to the genesis of plaque rupture and ischemic events. Contemporary data support that the risk associated with arterial inflammation persists independently of low-density lipoprotein cholesterol and triglyceride levels.9 The data from Reilly et al6 suggest that EPA could help address this component of residual cardiovascular risk. Analyses from REDUCE-IT show consistent clinical benefits of EPA across baseline levels of low-density lipoprotein cholesterol (and triglycerides, as noted in the previous text). Anti-inflammatory effects mediated by the adaptive immune modulation beyond those assessed by the biomarkers of innate immunity previously reported in REDUCE-IT, such as the effects on T cells reported by Reilly et al,6 could contribute to these benefits.

The valuable data from Reilly et al6 add to other important experimental data that have shown cell membrane stabilizing properties, other anti-inflammatory effects, antioxidant benefits, and antithrombotic properties of EPA, beyond its ability to lower levels of triglyceride-rich lipoproteins.8 These laboratory data complement several randomized imaging trials that also show effects of EPA on slowing or even reversing coronary plaque progression, including the first demonstration of an effect of any drug on improving noninvasively determined fractional flow reserve on CT angiography.10

The present analysis should prompt further research on EPA. This molecule, highly conserved through evolution, appears to play a fundamental role in cardiovascular biology. In REDUCE-IT, no apparent excess in infections emerged; thus, unlike some other targeted anti-inflammatory agents, there does not appear to be an infectious disease risk associated with EPA. This observation opens the door to the study of EPA in other disease states where the effects described by Reilly et al6 on T cells may also provide clinical benefit.

I think the scientific community has done a poor job of highlighting these OTHER trials (beyond JUST Reduce-It) that showed efficacy with IPE.

Now they just need to figure out how to commercialize it at scale, and convince a BP that it can be done.

Last sentence makes wonder if Nissen is pissed that the Cleveland Clinic has given grants to Dr. Mason. Thanks for posting.  Have a good workweek tomorrow

The results from JELIS, REDUCE-IT, RESPECT-EPA, EVAPORATE & CHERRY are now explained! It's the EPA Stupid!
https://www.sciencedirect.com/science/article/pii/S2452302X24003735

DMC, Amazing document. We are in good company. As Capt would say "it's the EPA stupid"
The credits list many companies, so surely someone has their eye on Amarin!

The deals are out there, M&A is picking up. Amarin is next!

Merck buys rights to heart disease drug in latest China deal
REUTERS 8:11 AM ET 3/25/2025
Symbol Last Price Change
MRK 91.43down -0.88 (-0.9533%)
LLY 864.38down -0.52 (-0.0601%)
ULIHF 2.1down -0.25 (-10.638298%)
QUOTES AS OF 10:37:00 AM ET 03/25/2025
By Sriparna Roy

March 25 (Reuters) - Merck(MRK) has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with China-based firms.

Large drugmakers including Merck(MRK) and Eli Lilly(LLY) have turned to Chinese biotechs for deals that give them access to new drugs for a cheaper investment, analysts have said.

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's(ULIHF) weight-loss drug candidate in a deal worth up to $2 billion.

Merck (MRK) last year signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat obesity. It also bought the rights to an early-stage cancer drug from China's LaNova in an up to $3.3 billion deal.

China continues to be an interesting source of recently struck licensing deals, as more innovations at low costs are coming out of the region, said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Merck(MRK) shares.

Under the latest deal, announced on Tuesday, Merck(MRK) will get exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals' experimental oral heart disease drug, HRS-5346, worldwide, except in the Greater China region.

The drug, currently being studied in a mid-stage trial in China, belongs to a class of drugs which prevent formation of cholesterol, fats and proteins in the blood, which can limit the blood flow to vital organs resulting in heart attack, stroke and other cardiovascular diseases.

Hengrui Pharma will receive an upfront payment of $200 million and will be eligible for up to $1.77 billion if it meets certain development, regulatory and commercial milestones, as well as royalties on net sales of HRS-5346, if approved.

The deal is expected to close in the second quarter of 2025. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta and Shinjini Ganguli)

https://stocktwits.com/SanDiegoLiving/message/609151985

https://www.sciencedirect.com/science/article/pii/S2452302X24003735?via%3Dihub

JRoon, the obvious thing to look for in the next ERs and shareholder meeting is mention of the dreaded and feared shelf offering. I'm too lazy and at this point way more interested in following names that don't trade in fractions of cents to look to see how many shares have already been approved and remain open in the current state.

Sleven, I am referring to authorizing new shares, not distributing currently approved, treasury shares (as they do to fund options and stock grants).

I believe authorizing new shares requires shareholder approval.

Either way, I don't see why they would do a new capital raise.

"And once the RS happens they will be able to sell shares to raise funds. One doesn't have to look too far to find companies which have done the same"

I would argue that one would have to look very far to find a case in which a company has executed a 1 for 20 and did not raise funds within a year of the RS.

Nuke
A fukn'men!

Jesus...the Whin meter has pegged out. Give it a rest. The finger pointing is not working? Conjecture on this board is amazing. If Sarissa and company were out to screw the small guy, the $300m cash would have been gone long ago. Before you babies get your diapers soiled. What exactly would you arm chair quarterbacks done any different? Then ask yourselves would your strategy have worked? Amarin is fighting battles on several fronts. The Generics, the PBMs, Big Pharma, the media, the courts. Seriously all you Business majors and ex-CEOs tell us your battle strategy. It's better than reading all the whining... 

Chk the laws in the UK and Ireland ...specifically the Companies Act and if avalyaibe the Co's bylaws . AMRN is an Irish Co
In the UK I think you need 75% of the share holders to approve a R/S and maybe 50% to approve dilution ...unless waived in bylaws.
Wall st would trash AMRN if they diluted now.. with around $260m ? cash on hand .
No position
JMO
Kiwi

The game has changed since Sarissa took over.

They found out that they couldn't run the ship any better and are now in a totally different mode. Recover their monies at all cost, including ours.

Yeah unfortunately I agree with you. I was rah rah about voting Blue on the proxy because the dude had invested $100 million, and the previous ownership never bought shares, but clearly he's willing to screw us to get his money back.

@JRoon shareholder approval is not necessary to dilute, just like it's not necessary for a RS.

So you are a parts delivery driver.

So am I but at Federated. I tell people I'm the CDO, Chief Delivery Officer.

The only time Sarissa/Denner cared about shareholders was during the proxy fight.

They were going to change everything if they got control. Well, we have seen how that worked out. Their behavior is exactly the same as
the prior management. We hear nothing.

And once the RS happens they will be able to sell shares to raise funds. One doesn't have to look too far to find companies which have done the same.

In fact some have done such a maneuver several times over and flushed shareholders completely out by successive reverse splits.

Now that others have posted along the same lines I feel safe in posting this....maybe.

JRoon, They do not require shareholder approval.
Sleven,

I still don't understand how/why they would do this. That makes no sense to me. They just got approval for a share BUYBACK. Raising more cash makes zero sense, and it would not gain shareholder approval.

Why not? He can sell another 20 million shares at $5-8 and add another $100 million of cash to their runway. Sell it to his buddies and he gets more tacit control of the company. There would only be 40 million shares outstanding. Rinse and repeat.

And, not to mention that if things continue as they are (very slow growth) management may decide that they want to acquire another asset (they have mentioned having some thought towards that) or to raise more funds to try various other means to boost business (more salespeople in the EU or advertising here or even figure they need another trial to prove Nissen's gang wrong). Who knows. But with only 20 million shares it gives them a lot of runway.

I am sticking it out here past the RS. Still worried shorts may drive this lower after RS but I do buy the argument that it is so undervalued it would not make much sense for that to happen (of course we know that market is not always rational). However, if there is any movement towards dilution afterwards, I am out. And will be deducting 3,000 on line 7 of the 1040 for every year of the few years I have left.

Hoping it doesn't come to that. My fond wish is for them to quickly turn a profit. A RS split means that the profit as expressed per share will sound much greater after the RS. But we have a ways to go to turn profitable. Hopefully by the end of the year.

At one time I thought about mounting a BMP 50 Cal. In the back. 😎

Why not? He can sell another 20 million shares at $5-8 and add another $100 million of cash to their runway. Sell it to his buddies and he gets more tacit control of the company. There would only be 40 million shares outstanding. Rinse and repeat.

My store is in Houston. 

Huh? Why would Amarin RAISE funds? I don't understand this post.

I think dilution is likely once the RS takes place. Much easier to raise funds at that level. Sadly Denner is clearly willing to cut our throat to get his money back.

I think dilution is likely once the RS takes place. Much easier to raise funds at that level. Sadly Denner is clearly willing to cut our throat to get his money back.

That store is likely in Houston area

Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis
https://www.nature.com/articles/s41586-025-08792-8

Abstract

Recent evidence shows elevated circulating long-chain ceramide levels predict atherosclerotic cardiovascular disease (ASCVD) independently of cholesterol1,2. Although targeting ceramide signaling may provide therapeutic benefits beyond the treatment of hypercholesterolemia, the underlying mechanism by which circulating ceramides aggravate ASCVD remains elusive. We examined whether circulating long-chain ceramides activate membrane G protein-coupled receptors (GPCRs) to exacerbate atherosclerosis. We performed a systematic screen combining G protein signaling quantification, bioinformatic analysis of GPCRs expression, and functional examination of NLRP3 inflammasome activation, and the results suggested CYSLTR2 and P2RY6 are potential endogenous receptors of C16:0 ceramide-evoked inflammasome activation in both endothelial cells and macrophages. We found that inhibiting CYSLTR2/P2RY6 genetically or pharmacologically alleviated ceramide-induced atherosclerosis aggravation. Additionally, increased ceramide levels correlated with the severity of coronary artery disease in patients with varying degrees of renal impairment. Notably, CYSLTR2/P2RY6 deficiency mitigated chronic kidney disease (CKD)-aggravated atherosclerosis in mice, without affecting cholesterol or ceramide levels. Structural analysis of the ceramide-CYSLTR2-Gq complexes revealed that both C16:0 and C20:0 ceramides bind within an inclined channel-like ligand binding pocket on CYSLTR2. We further revealed an unconventional mechanism underlying ceramides-induced CYSLTR2 activation and CYSLTR2-Gq interface. Overall, our study provided structural and molecular mechanisms that long-chain ceramides initiate transmembrane Gq and inflammasome signaling through directly binding to CYSLTR2 and P2RY6 receptors, and blocking these signaling may provide new therapeutic potential to treat atherosclerosis-related diseases.

Hey Capt'n......... does O'Reilly have this retrofit in stock? If not, do you know the lead time?

I had to come out of retirement also. Nice Jeep. Looks like a prepper jeep. Water, gun rack for the zombie apocalypse. :D) Not being nosy, what region of the country is your store. I liked working at Checker/Schucks/Kragen. You meet some really nice people. It's rewarding when you can help a diy get their vehicle back on the road. Of course you meet all kinds. I think everyone should work retail for at least 3 years. Then the A*holes wouldn't be such a*holes. That article posted by DAR was really touting Ezetimibe. Pushed of course by big pharma. 

WSJ has a very interesting article today, pages A1-A10, on people and companies they founded that are dealing with extension of life. Activation of sirtuins is the controversial topic mentioned with compounds like rapamycin, resveratrol, NAD boosters, pterostilbene, omega-3 and vitamin D3. Company and people names are Elysium, Sequoia Capital, Leonard Guarente, Buck Institute, Metro, Optispan, David Sinclair,  Eric Marcotulli, Eric Verdin, Matt Kaeberlein.  No mention of  U. Wisconsin, BRAVE trial, Amarin.